Fortress Biotech, Inc. Dividends Receivable
Fortress Biotech, Inc. (FBIO) had Dividends Receivable of $1.29 million as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes
us-gaap:DividendsReceivable · last filed 2026-03-31
- 2025-12-31: Dividends Receivable $1.29M.
- 2024-12-31: Dividends Receivable $10.85M.
- 2023-12-31: Dividends Receivable $6.35M; Dividends Receivable as first filed $5.11M.
- 2022-12-31: Dividends Receivable $3.87M.
| Period end | Dividends Receivable | Dividends Receivable as first filed |
|---|---|---|
| 2025-12-31 | $1.29M 10-K · filed 2026-03-31 | |
| 2024-12-31 | $10.85M 10-K · filed 2026-03-31 | |
| 2023-12-31 | $6.35M 10-K · filed 2025-03-31 | $5.11M 10-K · filed 2024-03-28 |
| 2022-12-31 | $3.87M 10-K · filed 2024-03-28 | |
| 2021-12-31 | $12.33M 10-K · filed 2023-03-31 | |
| 2020-12-31 | $13.07M 10-K · filed 2022-03-28 | $13.06M 10-K · filed 2021-03-31 |
| 2019-12-31 | $7.59M 10-K/A · filed 2021-04-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |